In the trial, the combination extended the time patients lived without their disease worsening compared with Tagrisso alone, meeting the study’s primary endpoint.
The trial included previously untreated patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) whose tumours had moderate to high levels of the MET biomarker.
BREAKING